BioStem Technologies ( (BSEM) ) has released its Q2 earnings. Here is a breakdown of the information BioStem Technologies presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioStem Technologies, Inc. is a MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, leveraging its proprietary BioREtain processing method.
In its preliminary second-quarter 2025 financial results, BioStem Technologies reported a net revenue of $49.3 million and achieved its sixth consecutive quarter of positive adjusted EBITDA, despite facing challenges from increased competition and reimbursement uncertainties.
Key financial highlights include a net revenue decrease of 34% compared to the previous year, primarily due to lower volumes in the wound care portfolio. The company reported a gross profit of $48.6 million, with operating expenses totaling $48.5 million. Adjusted EBITDA was $2.5 million, down from $10.1 million in Q2 2024, reflecting lower gross profit and increased research and development expenses.
Strategically, BioStem has expanded its intellectual property portfolio and appointed Brandon Poe as the new Chief Financial Officer. The company is also working towards uplisting to Nasdaq, with ongoing efforts to finalize its Form 10 and audit process.
Looking ahead, BioStem Technologies remains focused on its strategic objectives and market opportunities, with plans to address reimbursement challenges and continue its growth trajectory in the MedTech industry.